PMID- 29159080
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220310
IS  - 2214-6237 (Electronic)
IS  - 2214-6237 (Linking)
VI  - 1
IP  - 2
DP  - 2014 Jun
TI  - Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide 
      versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) 
      obese patients with type 2 diabetes mellitus.
PG  - 31-37
LID - 10.1016/j.jcte.2014.03.001 [doi]
AB  - OBJECTIVE: To compare the efficacy and safety of the once-daily prandial 
      glucagon-like peptide-1 receptor agonist lixisenatide with the dipeptidyl 
      peptidase-4 inhibitor sitagliptin in patients aged <50 years affected by obesity 
      and type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: This was a 24-week, 
      double-blind, randomized, parallel-group study. Obese patients with T2DM 
      inadequately controlled on metformin were randomized to lixisenatide 20 mug 
      once-daily injection (n = 158) or once-daily oral sitagliptin 100 mg (n = 161). 
      The primary endpoint was the proportion of patients with a glycated hemoglobin 
      (HbA(1c)) <7% and >/=5% weight loss at 24 weeks. RESULTS: The proportion of 
      patients that achieved the primary endpoint was 12.0% for lixisenatide versus 
      7.5% for sitagliptin; weighted average of proportion difference: 4.6%, 
      p = 0.1696). A total of 40.7% of patients achieved HbA(1c) <7% with lixisenatide 
      versus 40.0% with sitagliptin. Lixisenatide produced greater reductions in body 
      weight (LS mean difference: -1.3 kg, p = 0.0006) and postprandial plasma glucose 
      after a standardized meal test (LS mean difference: -34.4 mg/dL [-1.9 mmol/L], 
      p = 0.0001) versus sitagliptin. There was a similar incidence of 
      treatment-emergent adverse events (63.9% vs. 60.9%) and serious 
      treatment-emergent adverse events (1.9% vs. 1.9%), with low rates of symptomatic 
      hypoglycemia (0.6% vs. 1.9%) for lixisenatide and sitagliptin, respectively, and 
      no cases of severe hypoglycemia. CONCLUSION: In obese patients aged <50 years 
      with T2DM, the proportion of patients with an HbA(1c) <7% with weight loss >/=5% 
      was similar between groups. Lixisenatide, however, resulted in significantly 
      greater reductions in body weight and postprandial plasma glucose excursions than 
      sitagliptin. Tolerability was similar between groups.
FAU - Van Gaal, Luc
AU  - Van Gaal L
AD  - Antwerp University Hospital, Department of Endocrinology, Diabetology and 
      Metabolic Diseases, Wilrijkstraat 10, B-2650 Edegem, Antwerp, Belgium.
FAU - Souhami, Elisabeth
AU  - Souhami E
AD  - Sanofi, Paris, France.
FAU - Zhou, Tianyue
AU  - Zhou T
AD  - Sanofi, Bridgewater, NJ, USA.
FAU - Aronson, Ronnie
AU  - Aronson R
AD  - LMC Diabetes & Endocrinology, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
DEP - 20140411
PL  - Netherlands
TA  - J Clin Transl Endocrinol
JT  - Journal of clinical & translational endocrinology
JID - 101629335
PMC - PMC5685032
OTO - NOTNLM
OT  - AE, adverse event
OT  - BMI, body mass index
OT  - Body weight
OT  - DPP-4, dipeptidyl peptidase-4
OT  - FPG, fasting plasma glucose
OT  - GI, gastrointestinal
OT  - GLP-1, glucagon-like peptide-1
OT  - Glycated hemoglobin (HbA1c)
OT  - HbA1c, glycated hemoglobin
OT  - LOCF, last observation carried forward
OT  - LS, least squares
OT  - PPG, postprandial plasma glucose
OT  - Postprandial plasma glucose (PPG)
OT  - T2DM, type 2 diabetes mellitus
OT  - TEAE, treatment-emergent adverse event
EDAT- 2014/04/11 00:00
MHDA- 2014/04/11 00:01
PMCR- 2014/04/11
CRDT- 2017/11/22 06:00
PHST- 2014/01/08 00:00 [received]
PHST- 2014/03/11 00:00 [revised]
PHST- 2014/03/23 00:00 [accepted]
PHST- 2017/11/22 06:00 [entrez]
PHST- 2014/04/11 00:00 [pubmed]
PHST- 2014/04/11 00:01 [medline]
PHST- 2014/04/11 00:00 [pmc-release]
AID - S2214-6237(14)00011-8 [pii]
AID - 10.1016/j.jcte.2014.03.001 [doi]
PST - epublish
SO  - J Clin Transl Endocrinol. 2014 Apr 11;1(2):31-37. doi: 
      10.1016/j.jcte.2014.03.001. eCollection 2014 Jun.